1. Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis
- Author
-
Angela D. M. Kashuba, Amanda Poliseno, Tae-Wook Chun, Amanda P. Schauer, Anne F. Peery, Mackenzie L. Cottrell, Evan S. Dellon, Jessica L. Adams, Erin D Huiting, Kaitlyn A. Maffuid, Heather M.A. Prince, Craig Sykes, and Frank Z. Stanczyk
- Subjects
Adult ,0301 basic medicine ,Microbiology (medical) ,Adolescent ,Tenofovir diphosphate ,Anti-HIV Agents ,medicine.medical_treatment ,030106 microbiology ,Human immunodeficiency virus (HIV) ,Brief Reports and Commentary ,Physiology ,HIV Infections ,medicine.disease_cause ,Transgender Persons ,Young Adult ,03 medical and health sciences ,Pre-exposure prophylaxis ,0302 clinical medicine ,Hormone replacement therapy (female-to-male) ,Transgender ,medicine ,Humans ,Tissue Distribution ,030212 general & internal medicine ,Aged ,business.industry ,Adenine ,HIV ,Middle Aged ,Organophosphates ,Clinical trial ,Treatment Outcome ,Infectious Diseases ,Cohort ,Female ,Pre-Exposure Prophylaxis ,Hormone therapy ,Drug Monitoring ,business - Abstract
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP’s active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (ρ = –0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration . NCT02983110.
- Published
- 2019